Log in
NASDAQ:LPTX

Leap Therapeutics Stock Forecast, Price & News

$1.60
+0.01 (+0.63 %)
(As of 11/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.57
Now: $1.60
$1.66
50-Day Range
$1.49
MA: $1.86
$2.31
52-Week Range
$0.69
Now: $1.60
$3.18
Volume686,675 shs
Average Volume704,720 shs
Market Capitalization$95.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. Its clinical stage programs also include TRX518, a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Leap Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LPTX
CUSIPN/A
Phone617-714-0360
Employees24

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.07) per share

Profitability

Net Income$-32,900,000.00

Miscellaneous

Market Cap$95.45 million
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable
$1.60
+0.01 (+0.63 %)
(As of 11/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions

How has Leap Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Leap Therapeutics' stock was trading at $2.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LPTX stock has decreased by 20.4% and is now trading at $1.60.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Leap Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Leap Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Leap Therapeutics?

Wall Street analysts have given Leap Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Leap Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Leap Therapeutics' next earnings date?

Leap Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Leap Therapeutics
.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) posted its earnings results on Thursday, November, 12th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.04.
View Leap Therapeutics' earnings history
.

What price target have analysts set for LPTX?

5 brokerages have issued 12-month target prices for Leap Therapeutics' stock. Their forecasts range from $2.50 to $8.00. On average, they anticipate Leap Therapeutics' share price to reach $5.30 in the next year. This suggests a possible upside of 231.3% from the stock's current price.
View analysts' price targets for Leap Therapeutics
.

Who are some of Leap Therapeutics' key competitors?

What other stocks do shareholders of Leap Therapeutics own?

Who are Leap Therapeutics' key executives?

Leap Therapeutics' management team includes the following people:
  • Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec., Pres, CEO & Director (Age 51, Pay $577.3k)
  • Mr. Augustine J. Lawlor, Chief Operating Officer (Age 66, Pay $576.21k)
  • Dr. Cynthia A. Sirard, Chief Medical Officer (Age 50)
  • Mr. Mark O'Mahony, Chief Manufacturing Officer (Age 49)
  • Ms. Christine M. Granfield, VP and Head of Regulatory Affairs & Quality
  • Dr. Jason S. Baum Ph.D., VP & Head of Translational Medicine
  • Dr. Walter Newman, Sr. Research Fellow (Age 74)

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sphera Funds Management LTD. (1.34%), J. Goldman & Co LP (1.32%), Platinum Investment Management Ltd. (0.70%), BlackRock Inc. (0.18%), Squarepoint Ops LLC (0.11%) and Old Well Partners LLC (0.06%). Company insiders that own Leap Therapeutics stock include Christopher Mirabelli and Perceptive Advisors Llc.
View institutional ownership trends for Leap Therapeutics
.

Which major investors are selling Leap Therapeutics stock?

LPTX stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP, and Sphera Funds Management LTD..
View insider buying and selling activity for Leap Therapeutics
.

Which major investors are buying Leap Therapeutics stock?

LPTX stock was acquired by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., Squarepoint Ops LLC, BlackRock Inc., Old Well Partners LLC, and Wetherby Asset Management Inc.. Company insiders that have bought Leap Therapeutics stock in the last two years include Christopher Mirabelli, and Perceptive Advisors Llc.
View insider buying and selling activity for Leap Therapeutics
.

How do I buy shares of Leap Therapeutics?

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $1.60.

How big of a company is Leap Therapeutics?

Leap Therapeutics has a market capitalization of $95.45 million. The company earns $-32,900,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Leap Therapeutics employs 24 workers across the globe.

What is Leap Therapeutics' official website?

The official website for Leap Therapeutics is www.leaptx.com.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.